CRISPR Therapeutics for Duchenne Muscular Dystrophy.

Area of Science:

• Biotechnology
• Genetics
• Neuromuscular Disorders

Background:

• Duchenne muscular dystrophy (DMD) is a severe X-linked recessive disorder caused by mutations in the dystrophin gene, leading to progressive muscle degeneration.
• The absence of functional dystrophin protein results in muscle weakness, loss of ambulation, cardiomyopathy, and premature death.

Purpose of the Study:

• To review the application of clustered regularly interspaced short palindromic repeats (CRISPR) gene editing technology as a potential therapeutic strategy for Duchenne muscular dystrophy.
• To discuss the mechanisms, advancements, and challenges associated with CRISPR-based gene editing for DMD.

Main Methods:

• Review of in vitro and in vivo studies investigating CRISPR-mediated gene editing for DMD.
• Discussion of various CRISPR system modifications, including base and prime editing, for enhanced precision.
• Analysis of factors influencing gene editing efficiency, such as cell cycle stage and DNA template presence.

Main Results:

• CRISPR gene editing demonstrates potential to correct DMD-causing mutations by restoring the dystrophin gene reading frame.
• Studies have shown successful application of CRISPR in both laboratory and animal models of DMD.
• Novel CRISPR variants like base and prime editors offer improved precision for gene correction.

Conclusions:

• CRISPR gene editing is a promising therapeutic avenue for Duchenne muscular dystrophy, with the potential for permanent mutation correction.
• Key challenges including delivery efficiency, off-target effects, and long-term protein expression must be addressed.
• Further research on the safety and accuracy of CRISPR systems is crucial for successful clinical translation.